7910 Woodmont Avenue,Suite 1210
Bethesda, Maryland 20814, U.S.A. 
info@mlsvfund.com |   +1 301 298 5455

© 2018  by MASA Life Science Ventures, LP


Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals is a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic compounds for autoimmune and inflammatory diseases. Apellis’ approach is centered on the inhibition of the complement system, which is a cascade of interacting proteins and is an integral component of the immune system. Utilizing technology exclusively licensed from the Trustees of the University of Pennsylvania, the company is developing products to treat paroxysmal nocturnal hemoglobinuria (also known as PNH), geographic atrophy (GA), intermediate age-related macular degeneration (intermediate AMD) and chronic obstructive pulmonary disease (COPD). Apellis was spun out of Potentia Pharmaceuticals Inc. in 2010.  In November 2014 Apellis then acquired the rights to the APL-2 for AMD from Potentia. The company is headquartered in Crestwood, Kentucky.

Cytox, Ltd.

Cytox Limited is developing a unique scientific and proprietary technology platform for the diagnosis and treatment of Alzheimer’s disease (AD) and related diseases. Through the application of its proprietary scientific platform, the company is elucidating the biology and genetics behind dementia, as well as developing prognostics tests for cognitive decline and individual risk of developing AD or other dementias.  In partnership with Affymetrix (a division of Thermo Fishe Scientific), Cytox has developed its first product to assess AD risk and is currently being sold in the research market.  Cytox is headquartered in Oxford, United Kingdom.

enGene, Inc.

enGene Inc. is a privately held biotechnology company developing a versatile, proprietary nonviralvector platform for gene delivery to mucosal cells lining the gut. The vector system can beadministered to the intestine via the oral or enema route. enGene is developing its unique genedelivery formulation into an orally available “Gene Pill”, which has the potential to be a platformfor oral delivery of a wide range of protein drugs. Its primary focus is targeting its technology toenable localize delivery of immune-modulating proteins to the gut for treating various immunedisorders.  enGene is headquartered in Montreal Canada.

MaxCyte, Inc.

MaxCyte®, Inc., a leader in cell transfection, develops and markets cell engineering technology to biotechnology and pharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno‐oncology.  The company's patented flow electroporation technology enables its products to deliver fast, reliable and scalable cell engineering to drive the research and clinical development of a new generation of cell-based medicines.  Using the unique capabilities of its technology and vast experience in cell engineering, MaxCyte is developing CARMA, its proprietary platform in immuno-oncology, to deliver a validated non-viral approach to CAR therapies across a broad range of cancer indications, including solid tumors where existing CAR­‐T approaches face significant challenges.  Maxcyte is headquartered in Gaithersburg, Maryland.